Vogenx Announces Financial Results for Q3 2026

Vogenx, Inc. disclosed its financial performance for the third quarter of 2026. The company highlighted key developments, including the initiation of the EMERGE study and strategic personnel enhancements. The company commenced its EMERGE Phase 2b clinical trial for mizagliflozin, targeting post-bariatric hypoglycemia (PBH), with results anticipated in late 2027.

Vogenx's financial position was bolstered by a $93.4 million IPO in August 2026, netting $84.4 million after expenses. As of September 30, 2026, cash reserves and marketable securities amounted to $82.1 million, a drastic increase from the previous year-end's $601,000.

Costs rose due to increased research and development expenses, which climbed to $1.1 million, largely due to the EMERGE study. General and administrative expenses saw a rise as well. The quarter ended with a net loss of $4.9 million, primarily due to increased operating expenses and changes in warrant liabilities.